Eficiencia Comparada de los Agentes anti-factor de Necrosis Tumoral, Biológicos con un Modo de Acción Alternativo y Tofacitinib en una coorte observacional de pacientes con artritis reumatoide en Suiza
RMD Open 2020;6:e001174 doi:10.1136/rmdopen-2020-001174
This nested cohort study found that, in Switzerland, there was a generally limited overall drug maintenance for b/tsDMARD options in RA. Using data from SCQM-RA – a prospective longitudinal registry, overall maintenance (drug survival) was calculated for TNFi, bDMARD-OMA or JAKi in patients with RA.After adjusting for potential confounding factors, there was a higher hazard of drug discontinuation with TNFi compared with tofacitinib; no significant difference was observed between non-TNF bDMARDs...